Difference between revisions of "Tachi Yamada"

From Wikispooks
Jump to navigation Jump to search
m (Text replacement - "He served as " to "He was ")
(general tidy)
 
(One intermediate revision by one other user not shown)
Line 16: Line 16:
 
|political_parties=
 
|political_parties=
 
|employment={{job
 
|employment={{job
|title=
+
|title=President of the Global Health Program
|start=
+
|start=2005
|end=
+
|end=2011
}}{{job
+
|employer=Bill & Melinda Gates Foundation
|title=
 
|start=
 
|end=
 
 
}}
 
}}
 
}}
 
}}
'''Tadataka''' "'''Tachi'''" '''Yamada''' was a Japanese-born American physician and gastroenterologist.  
+
'''Tadataka''' "'''Tachi'''" '''Yamada''' was a Japanese-born American physician and gastroenterologist. Yamada was Chairman of Research and Development and member of the Board of Directors at [[GlaxoSmithKline]] (GSK) before becoming the President of the Global Health Program at the [[Bill & Melinda Gates Foundation]] between 2005-2011.
Yamada served as Chairman of Research and Development and was a member of the Board of Directors at [[GlaxoSmithKline]] (GSK) before becoming the President of the Global Health Program at the [[Bill & Melinda Gates Foundation]].
 
  
At GSK, Yamada was responsible for intimidating and silencing scientist [[John Buse]], who had warned of the deadly effects of the drug diabetes medicine Avandia: “I think there are two courses of action. One is to sue him for knowingly defaming our product even after we have set him straight as to the facts—the other is to launch a well-planned offensive on behalf of Avandia."
+
At GSK, Yamada was responsible for intimidating and silencing scientist [[John Buse]], who had warned of the deadly effects of the [[diabetes]] drug [[Avandia]]: "I think there are two courses of action. One is to sue him for knowingly defaming our product even after we have set him straight as to the facts-the other is to launch a well-planned offensive on behalf of Avandia."
  
At the time of his death, he was a venture partner of [[Frazier Healthcare Partners]], a venture capital company among other things owning healthcare providers in [[US prisons]].<ref>https://blogs.wsj.com/privateequity/2012/08/02/even-in-prison-private-equity-is-king/</ref>
+
At the time of his death, he was a venture partner of [[Frazier Healthcare Partners]], a venture capital company among other things owning healthcare providers in [[US prisons]].<ref>https://blogs.wsj.com/privateequity/2012/08/02/even-in-prison-private-equity-is-king/</ref> He was also Chairman of the Board of the [[Clinton Health Access Initiative]].
 
 
He was also Chairman of the Board of the [[Clinton Health Access Initiative]].
 
  
 
==Early life and education==
 
==Early life and education==
Line 42: Line 36:
  
 
==Career==
 
==Career==
Yamada served as Chairman of Research and Development and was a member of the Board of Directors at [[GlaxoSmithKline]], where he was responsible for intimidating and silencing scientist [[John Buse]].
+
Yamada worked as Chairman of Research and Development and was a member of the Board of Directors at [[GlaxoSmithKline]], where he was responsible for intimidating and silencing scientist [[John Buse]].
  
He then joined the [[Bill & Melinda Gates Foundation]], where he was President of the Global Health Program from 2005 to 2011<ref name=geek>https://www.geekwire.com/2021/tadataka-yamada-1945-2021-pioneer-drug-development-led-global-health-gates-foundation/</ref>. In this capacity he oversaw grants totaling over $9 billion in programs directed at applying technologies i.e. [[vaccines]]) to address major health challenges of the developing world including TB, [[HIV]], [[malaria]] and other infectious diseases, malnutrition and maternal and child health.  
+
He then joined the [[Bill & Melinda Gates Foundation]], where he was President of the Global Health Program from 2005 to 2011<ref name=geek>https://www.geekwire.com/2021/tadataka-yamada-1945-2021-pioneer-drug-development-led-global-health-gates-foundation/</ref>. In this capacity he oversaw grants totaling over $9 billion in programs directed at "applying technologies", (i.e. mostly [[vaccines]]), in reality a power grab under the guise of claiming to address major health challenges of the developing world.
  
Yamada was then Executive Vice-President and a Board Member of [[Takeda Pharmaceuticals]], and served as the Chief Medical and Scientific Officer of the company.
+
Yamada was then Executive Vice-President and a Board Member of [[Takeda Pharmaceuticals]], where he worked as Chief Medical and Scientific Officer of the company.
  
 
At the time of his death, he was a venture partner of [[Frazier Healthcare Partners]], a venture capital company among other things owning in healthcare providers in [[US prisons]].<ref>https://blogs.wsj.com/privateequity/2012/08/02/even-in-prison-private-equity-is-king/</ref>
 
At the time of his death, he was a venture partner of [[Frazier Healthcare Partners]], a venture capital company among other things owning in healthcare providers in [[US prisons]].<ref>https://blogs.wsj.com/privateequity/2012/08/02/even-in-prison-private-equity-is-king/</ref>
Line 54: Line 48:
 
Yamada was also board chair of vaccine company [[Icosavax]], a [[University of Washington]] spinout which he co-founded.<ref name=geek/>
 
Yamada was also board chair of vaccine company [[Icosavax]], a [[University of Washington]] spinout which he co-founded.<ref name=geek/>
  
He also served as a member of the [[President’s Council of Advisors on Science and Technology]], Vice-Chair of the Council of the National Academy of Medicine (US), President of the Association of American Physicians and President of the [[American Gastroenterological Association]]. He was a member of the Board of the [[University of Michigan Health System]] and as Chairman of the Board of the [[Clinton Health Access Initiative]].
+
He was also a member of the [[President’s Council of Advisors on Science and Technology]], Vice-Chair of the Council of the National Academy of Medicine (US), President of the Association of American Physicians and President of the [[American Gastroenterological Association]]. He was a member of the Board of the [[University of Michigan Health System]] and as Chairman of the Board of the [[Clinton Health Access Initiative]].
  
 
==Honors==
 
==Honors==

Latest revision as of 07:38, 14 December 2022

Person.png Tachi YamadaRdf-entity.pngRdf-icon.png
(doctor, health bureaucrat)
Tachi Yamada.jpg
Born5 June 1945
Tokyo, Japan
Died4 August 2021 (Age 76)
Seattle, Washington, U.S.
NationalityUS
Alma materPhillips Academy, Stanford University, New York University
Member ofCouncil on Foreign Relations/Members 3
Interests • Bill & Melinda Gates Foundation
• GlaxoSmithKline
• United States Army Medical Research Institute of Infectious Diseases
• Takeda
• Clinton Health Access Initiative
Interest ofJohn Buse
Chairman of Research and Development and was a member of the Board of Directors at GlaxoSmithKline where he intimidated and silenced a researcher warning of a deadly drug.

After that he become the President of the Global Health Program at the Bill & Melinda Gates Foundation. Also Chairman of the Board of the Clinton Health Access Initiative.

Tadataka "Tachi" Yamada was a Japanese-born American physician and gastroenterologist. Yamada was Chairman of Research and Development and member of the Board of Directors at GlaxoSmithKline (GSK) before becoming the President of the Global Health Program at the Bill & Melinda Gates Foundation between 2005-2011.

At GSK, Yamada was responsible for intimidating and silencing scientist John Buse, who had warned of the deadly effects of the diabetes drug Avandia: "I think there are two courses of action. One is to sue him for knowingly defaming our product even after we have set him straight as to the facts-the other is to launch a well-planned offensive on behalf of Avandia."

At the time of his death, he was a venture partner of Frazier Healthcare Partners, a venture capital company among other things owning healthcare providers in US prisons.[1] He was also Chairman of the Board of the Clinton Health Access Initiative.

Early life and education

Yamada was born in Tokyo, a grandson of one of the first people of Japanese descent to be fully trained as an American physician, and completed his education in the United States. After attending Phillips Academy[2] for his high school education, he graduated from Stanford University with a BA in history and obtained his M.D. from New York University School of Medicine. He completed his internal medicine training at the Medical College of Virginia.

He then became an investigator in the United States Army Medical Research Institute of Infectious Diseases holding the rank of Major, U.S. Army Medical Corps.

Subsequently, he trained in gastroenterology at the UCLA School of Medicine and assumed his first faculty position there. He later moved to the University of Michigan where he headed the Gastroenterology Division and ultimately became Chairman, Department of Internal Medicine and Physician-in-Chief of the University of Michigan Medical Center before joining GlaxoSmithKline.

Career

Yamada worked as Chairman of Research and Development and was a member of the Board of Directors at GlaxoSmithKline, where he was responsible for intimidating and silencing scientist John Buse.

He then joined the Bill & Melinda Gates Foundation, where he was President of the Global Health Program from 2005 to 2011[3]. In this capacity he oversaw grants totaling over $9 billion in programs directed at "applying technologies", (i.e. mostly vaccines), in reality a power grab under the guise of claiming to address major health challenges of the developing world.

Yamada was then Executive Vice-President and a Board Member of Takeda Pharmaceuticals, where he worked as Chief Medical and Scientific Officer of the company.

At the time of his death, he was a venture partner of Frazier Healthcare Partners, a venture capital company among other things owning in healthcare providers in US prisons.[4]

Among his many other activities he was a member of the Board of Directors of corporations across four continents and was a member of the Board of Agilent Technologies and chaired the Boards of Phathom Pharmaceuticals and Passage Bio, two companies for which he was a founder.

Yamada was also board chair of vaccine company Icosavax, a University of Washington spinout which he co-founded.[3]

He was also a member of the President’s Council of Advisors on Science and Technology, Vice-Chair of the Council of the National Academy of Medicine (US), President of the Association of American Physicians and President of the American Gastroenterological Association. He was a member of the Board of the University of Michigan Health System and as Chairman of the Board of the Clinton Health Access Initiative.

Honors

Yamada received an honorary appointment as Knight Commander of the Most Excellent Order of the British Empire.

He was a fellow of the Imperial College London, a Master of the American College of Physicians and a Fellow of the Royal College of Physicians; and gave the last centenary lecture at Imperial College London in March 2008, which was chaired by Sir Richard Sykes.

He was also the recipient of numerous awards, including the Smith Kline & French Award in Gastrointestinal Physiology from the American Physiological Society, the Julius Friedenwald Medal from the American Gastroenterological Association, the Distinguished Faculty Achievement Award from the University of Michigan,[5] the Distinguished Medical Scientist Award from the Medical College of Virginia and the August M. Watanabe Prize in Translational Research from the Indiana University School of Medicine.

He was awarded honorary doctorates by the University of Michigan, University of East Anglia, the University of Warwick, Washington College, and Loyola University of Chicago.

In recognition of his contributions to medicine and science he was elected to membership in the National Academy of Medicine (US) and the National Academy of Medicine (Mexico) and to Fellowship in the Academy of Medical Sciences (UK) and the American Academy of Arts and Sciences.

Yamada was conferred the title Honorary Citizen of Singapore in 2016;[6] and the Order of the Rising Sun, Gold and Silver Stars, from the Japanese Government.



 

Events Participated in

EventStartEndLocation(s)Description
WEF/Annual Meeting/201126 January 201130 January 2011World Economic Forum
Switzerland
2229 guests in Davos, with the theme: "Shared Norms for the New Reality".
WEF/Annual Meeting/201225 January 201229 January 2012Switzerland2113 guests in Davos
WEF/Annual Meeting/201323 January 201327 January 2013World Economic Forum
Switzerland
2500 mostly unelected leaders met to discuss "leading through adversity"
WEF/Annual Meeting/201422 January 201425 January 2014World Economic Forum
Switzerland
2604 guests in Davos considered "Reshaping The World"
Many thanks to our Patrons who cover ~2/3 of our hosting bill. Please join them if you can.


References